Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.

Gu L, Jin X, Liang H, Yang C, Zhang Y

Open source

DOI
10.1016/j.phrs.2023.106789
Published
2023 Jun
Container
Pharmacological research
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.phrs.2023.106789,
  title = {Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.},
  author = {Gu L and Jin X and Liang H and Yang C and Zhang Y},
  year = {2023},
  journal = {Pharmacological research},
  doi = {10.1016/j.phrs.2023.106789},
  url = {https://doi.org/10.1016/j.phrs.2023.106789}
}

RIS

TY  - JOUR
TI  - Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.
AU  - Gu L
AU  - Jin X
AU  - Liang H
AU  - Yang C
AU  - Zhang Y
PY  - 2023
JO  - Pharmacological research
DO  - 10.1016/j.phrs.2023.106789
UR  - https://doi.org/10.1016/j.phrs.2023.106789
ER  - 

APA

L, G., X, J., H, L., C, Y., & Y, Z. (2023). Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.. Pharmacological research. https://doi.org/10.1016/j.phrs.2023.106789

Source records